Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gert-Jan van Ommen

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Current Opinion in Molecular Therapeutics|April 4, 2008
The therapeutic potential of antisense-mediated exon skippingGert-Jan van Ommen, Judith van Deutekom, Annemieke Aartsma-Rus
European Journal of Epidemiology|October 8, 2017
Chronic disease research in Europe and the need for integrated population cohortsPaul Brennan, Markus Perola, Gert-Jan van Ommen, et al.
Handbook of Clinical Neurology|April 30, 2013
Innovating therapies for muscle diseasesAnnemieke Aartsma-Rus, Gert-Jan Van Ommen, Jean-Claude Kaplan
The Lancet. Oncology|March 26, 2013
Patients would benefit from simplified ethical review and consent procedureMats G Hansson, Gert Jan van Ommen, Ruth Chadwick, et al.
European Journal of Human Genetics : EJHG|August 3, 2019
Meeting report: The Human Genome Meeting (HGM) 2019 in Seoul, KoreaAngela Solano, Giuseppe Novelli, Shruti Baghat, et al.
Human Genomics|August 3, 2019
Meeting report: the Human Genome Meeting (HGM) 2019 in Seoul, KoreaAngela Solano, Giuseppe Novelli, Shruti Baghat, et al.
Human Mutation|January 22, 2009
Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutationsAnnemieke Aartsma-Rus, Ivo Fokkema, Jan Verschuuren, et al.
Neuromuscular Disorders : NMD|March 24, 2010
A 3 months mild functional test regime does not affect disease parameters in young mdx miceMaaike van Putten, Christa de Winter, Willeke van Roon-Mom, et al.
Nucleic Acids Research|September 21, 2010
mRNA degradation controls differentiation state-dependent differences in transcript and splice variant abundancePeter A C 't Hoen, Michael Hirsch, Emile J de Meijer, et al.
Medicine|August 10, 2002
Predictability of age at onset in Huntington disease in the Dutch populationAnneke Maat-Kievit, Minique Losekoot, Koos Zwinderman, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Current Opinion in Molecular Therapeutics|April 4, 2008
The therapeutic potential of antisense-mediated exon skippingGert-Jan van Ommen, Judith van Deutekom, Annemieke Aartsma-Rus
European Journal of Epidemiology|October 8, 2017
Chronic disease research in Europe and the need for integrated population cohortsPaul Brennan, Markus Perola, Gert-Jan van Ommen, et al.
Handbook of Clinical Neurology|April 30, 2013
Innovating therapies for muscle diseasesAnnemieke Aartsma-Rus, Gert-Jan Van Ommen, Jean-Claude Kaplan
The Lancet. Oncology|March 26, 2013
Patients would benefit from simplified ethical review and consent procedureMats G Hansson, Gert Jan van Ommen, Ruth Chadwick, et al.
European Journal of Human Genetics : EJHG|August 3, 2019
Meeting report: The Human Genome Meeting (HGM) 2019 in Seoul, KoreaAngela Solano, Giuseppe Novelli, Shruti Baghat, et al.
Human Genomics|August 3, 2019
Meeting report: the Human Genome Meeting (HGM) 2019 in Seoul, KoreaAngela Solano, Giuseppe Novelli, Shruti Baghat, et al.
Human Mutation|January 22, 2009
Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutationsAnnemieke Aartsma-Rus, Ivo Fokkema, Jan Verschuuren, et al.
Neuromuscular Disorders : NMD|March 24, 2010
A 3 months mild functional test regime does not affect disease parameters in young mdx miceMaaike van Putten, Christa de Winter, Willeke van Roon-Mom, et al.
Nucleic Acids Research|September 21, 2010
mRNA degradation controls differentiation state-dependent differences in transcript and splice variant abundancePeter A C 't Hoen, Michael Hirsch, Emile J de Meijer, et al.
Medicine|August 10, 2002
Predictability of age at onset in Huntington disease in the Dutch populationAnneke Maat-Kievit, Minique Losekoot, Koos Zwinderman, et al.
Pageof 3